Hana Biosciences Granted Orphan Drug Designation for Melanoma Drug
Posted on: Tuesday, 1 July 2008, 09:01 CDT
Hana Biosciences has announced that the FDA has granted orphan drug designation for Marqibo for the treatment of adult patients with metastatic uveal melanoma.
Orphan drug designation offers significant benefits to Hana Biosciences, including financial incentives and market exclusivity for a period of seven years.
Hana is currently conducting a Phase II clinical trial to assess the efficacy of Marqibo as determined by disease control rate (complete response, partial response and durable stable disease) in patients with metastatic malignant uveal melanoma.
Anne Hagey, vice president and chief medical officer of Hana, said: "We are pleased to have received orphan designation from the FDA for Marqibo in metastatic uveal melanoma, a cancer with a clear unmet medical need. We believe this recognizes the need to pursue these difficult disease indications."
Source: Datamonitor
Related Articles
- Hana Biosciences' Marqibo Receives Orphan Designation From European Commission for the Treatment of Adult Acute Lymphoblastic Leukemia
- Hana Biosciences Receives U.S. Orphan Drug Designation for Marqibo for the Treatment of Metastatic Uveal Melanoma; Marqibo Currently in Phase 2 Clinical Trial for Metastatic Uveal Melanoma
- Hana Biosciences' Phase 2 Clinical Trial of Marqibo for Metastatic Uveal Melanoma Meets Clinical Response Criteria to Advance to Full Enrollment
- AmpliMed Corporation Announces Promising 1-Year Survival Data From Phase I/II Study of Amplimexon(R) in Metastatic Malignant Melanoma
- Hana Initiates Marqibo Phase II Melanoma Trial
- Hana Biosciences Initiates Marqibo Phase 2 Clinical Trial in Metastatic Malignant Uveal Melanoma
- SciClone and Sigma-Tau Present Encouraging Interim Phase 2 Metastatic Malignant Melanoma Response Data
- GammaCan International and Life Therapeutics Announce the Signing of a Term Sheet for the Development of VitiGam
- GammaCan Announces Positive Pre-IND Meeting With the U.S. FDA Regarding VitiGam - the Company's Novel Treatment for Metastatic Malignant Melanoma
 |
 |
User Comments (0)
RSS Feeds